Alcobra Files For $100M NASDAQ Offering

July 17, 2014 | Alcobra Pharmaceuticals filed a prospectus for a $100 million offering on NASDAQ. The company has developed alternative drugs for the treatment of ADHD based on its research. In May 2013, Alcobra’s IPO raised $25 million at a company value of $89 million. As of today, Alcobra is worth $260 million. The filing for the offering comes as Alcobra announces patient recruitment for Phase III clinical trials for its treatment for ADHD.